CETAPHIL_1170x120

Osteo Bi-Flex plays doubles with Chris Evert

Print Friendly, PDF & Email

NEW YORK — Osteo Bi-Flex has announced a partnership with world renowned, seven-time No. 1 professional tennis player Chris Evert. Together with Osteo Bi-Flex, Evert will help reinforce the brand’s commitment to leading the call for movement.

“With 157 singles titles and 18 grand slams under her belt, Chris Evert knows quite a few things about dedication, perseverance and what it takes to stay at the top of her game. We are thrilled to align ourselves with a powerhouse such as Chris,” Chris O’Connor, vice president of brand marketing for Osteo Bi-Flex said in a statement. “Osteo Bi-Flex is dedicated to producing products that help people stay as active physically as they are mentally, and Chris truly embodies this, making her the ideal brand advocate.”

This recent brand partnership is the next stage in Osteo Bi-Flex’s commitment to leading the call for movement; supporting and encouraging millions of Americans to continue doing the activities they enjoy most in life. After years of playing professional tennis, Evert aims to keep as active as she can in her current role of educating aspiring tennis players.

However, over time the game can place repeated stress on the body, including the joints, causing many players to be concerned about their joint health. Evert has spent her entire tennis career doing what she loves and aims to continue doing so.

“Ever since I was young I knew that I wanted to devote my life to tennis. Having started in the sport with my father, my love of the game is in my blood and it’s something that I truly enjoy doing on a daily basis,” said Chris Evert.

“Even though I am getting older, I never want to stop playing the game that I love, and I have no plans of slowing down. I’m excited to partner with Osteo Bi-Flex because they understand that we were made to move and support joint comfort so you can continue living your life to the fullest and doing what you love.”


McClane_728x90

VAG_728x90

Comments are closed.